ArticleEClinicalMedicine2025

Safety, reactogenicity, and immunogenicity of Ad26.COV2.S co-administered with a quadrivalent standard-dose or high-dose seasonal influenza vaccine: a non-inferiority randomised controlled trial.

Gabriela Tapia-Calle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.